ATE458491T1 - Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin - Google Patents

Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin

Info

Publication number
ATE458491T1
ATE458491T1 AT06802456T AT06802456T ATE458491T1 AT E458491 T1 ATE458491 T1 AT E458491T1 AT 06802456 T AT06802456 T AT 06802456T AT 06802456 T AT06802456 T AT 06802456T AT E458491 T1 ATE458491 T1 AT E458491T1
Authority
AT
Austria
Prior art keywords
oxytocin
administration
treating headache
headache
treatment
Prior art date
Application number
AT06802456T
Other languages
English (en)
Inventor
David Yeomans
Martin Angst
William Frey
Daniel Jacobs
Original Assignee
Univ Leland Stanford Junior
Healthpartners Res Foundation
Trigemina Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Healthpartners Res Foundation, Trigemina Inc filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE458491T1 publication Critical patent/ATE458491T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
AT06802456T 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin ATE458491T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71195005P 2005-08-26 2005-08-26
US79400406P 2006-04-21 2006-04-21
PCT/US2006/033500 WO2007025249A2 (en) 2005-08-26 2006-08-28 Methods for treatment of headaches by administration of oxytocin

Publications (1)

Publication Number Publication Date
ATE458491T1 true ATE458491T1 (de) 2010-03-15

Family

ID=37654909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06802456T ATE458491T1 (de) 2005-08-26 2006-08-28 Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin

Country Status (9)

Country Link
US (9) US20070093420A1 (de)
EP (3) EP2179741B1 (de)
JP (4) JP2009506076A (de)
AT (1) ATE458491T1 (de)
AU (1) AU2006282799B2 (de)
CA (2) CA2620364A1 (de)
DE (1) DE602006012513D1 (de)
IL (1) IL189777A0 (de)
WO (2) WO2007025286A2 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
CA2620364A1 (en) 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
KR101441693B1 (ko) 2005-10-18 2014-09-25 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및사용 방법
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
US20080261893A1 (en) * 2006-02-24 2008-10-23 Denise Barbut Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
WO2007120485A2 (en) * 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
GB2438834A (en) 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2680704A1 (en) * 2007-03-12 2008-09-18 Sarentis Therapeutics, Inc. Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
US8551968B2 (en) * 2007-03-13 2013-10-08 National Jewish Health Methods for generation of antibodies
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
EP2152240A4 (de) * 2007-06-08 2012-05-09 Healthpartners Res Foundation Pharmazeutische zusammensetzungen und verfahren für verstärktes abzielen therapeutischer verbindungen auf das zentralnervensystem
WO2009012376A1 (en) * 2007-07-17 2009-01-22 The Ohio State University Research Foundation Compositions and methods for skin care
AU2008297893A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a deslorelin and mastoparan as a therapeutic agent
WO2009033489A2 (en) * 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
CA2699177A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2188015A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung von salusin beta allein oder in kombination mit octreotid als therapeutisches mittel
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
WO2009145956A2 (en) * 2008-03-06 2009-12-03 The Trustees Of Columbia University In The City Of New York Uses of calpain inhibitors to inhibit inflammation
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
WO2010029555A1 (en) * 2008-09-12 2010-03-18 Slender Medical, Ltd. Virtual ultrasonic scissors
WO2010029441A2 (en) * 2008-09-15 2010-03-18 Optinose As Nasal delivery
EP2349241B1 (de) * 2008-10-17 2019-06-19 Signature Therapeutics, Inc. Pharmazeutische zusammensetzungen mit abgeschwächter freisetzung phenolischer opioide
WO2010090628A2 (en) * 2008-12-08 2010-08-12 Biousian Biotechnology, Inc Delta-opioid receptor selective analgesics
EP3620154A1 (de) * 2009-02-06 2020-03-11 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
EP2450036B1 (de) 2009-07-02 2016-06-15 Yamaguchi University Oberflächennarkosemittel
AU2010281436B2 (en) 2009-07-27 2016-03-24 Tonix Pharma Limited. Methods for treatment of pain
FR2948809B1 (fr) * 2009-07-31 2012-08-17 St Microelectronics Rousset Amplificateur de lecture faible puissance auto-minute
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
AU2010330747B2 (en) * 2009-12-18 2016-08-11 Achelios Therapeutics, Inc. Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8622993B2 (en) * 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
US20110184322A1 (en) * 2010-01-22 2011-07-28 Slender Medical Ltd. Method and device for treatment of keloids and hypertrophic scars using focused ultrasound
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011133178A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
WO2011133348A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
WO2011133179A1 (en) * 2010-04-21 2011-10-27 Pharmacofore, Inc Compositions comprising enzyme-cleavable hydromorphone prodrug
US8956346B2 (en) 2010-05-14 2015-02-17 Rainbow Medical, Ltd. Reflectance-facilitated ultrasound treatment and monitoring
US8617150B2 (en) 2010-05-14 2013-12-31 Liat Tsoref Reflectance-facilitated ultrasound treatment
US9242122B2 (en) 2010-05-14 2016-01-26 Liat Tsoref Reflectance-facilitated ultrasound treatment and monitoring
CN102905720A (zh) 2010-05-18 2013-01-30 日内瓦大学 催产素样分子的新用途及相关的方法
WO2012003968A1 (en) * 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
CN105078973B (zh) 2010-08-27 2020-10-09 尼昂克技术公司 包含poh衍生物的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
GB201015371D0 (en) * 2010-09-14 2010-10-27 Optinose As Nasal delivery
US8647661B1 (en) * 2010-11-05 2014-02-11 Florida A&M University Surface modified multilayered nanostructures for dermal delivery
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
CN103384472B (zh) 2011-01-11 2016-01-20 特色疗法股份有限公司 包含酶可裂解的羟考酮药物前体的组合物
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US20120183580A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic Composition for Transbuccal Administration
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US10687975B2 (en) * 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
BR112013022946A2 (pt) 2011-03-09 2017-07-18 Signature Therapeutics Inc pró-fármacos de agentes ativos com ligantes heterocíclocos
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
WO2012123819A1 (en) 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
EP2694049B1 (de) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol zur vorbeugung der schmerzchronifizierung
ES2989433T3 (es) * 2011-04-05 2024-11-26 Gruenenthal Gmbh Tapentadol para usar en el tratamiento del dolor asociado con neuralgia del trigémino
NO2701693T3 (de) 2011-04-29 2018-01-20
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) * 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
CA2856451A1 (en) * 2012-01-05 2013-07-11 Beech Tree Labs, Inc. Method of treating pain by administration of nerve growth factor
US9707414B2 (en) 2012-02-14 2017-07-18 Rainbow Medical Ltd. Reflectance-facilitated ultrasound treatment and monitoring
EP2814474B1 (de) 2012-02-15 2020-11-18 The United States of America, as Represented By the Secretery, Department of Health and Human Services Verfahren zur behandlung und prävention von erkrankungen und störungen des zentralnervensystems
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014068577A2 (en) 2012-11-05 2014-05-08 Rainbow Medical Ltd. Controlled tissue ablation
EP2926137B1 (de) * 2012-11-28 2019-05-29 Nektar Therapeutics Verfahren zur beurteilung und vorhersage der wirksamkeit einer brustkrebsbehandlung mit einem langwirkenden topoisomerase i-inhibitor
US9050330B2 (en) * 2012-12-06 2015-06-09 Jose C. Ramon-de-Jesus Method, composition and kit for treating frequent headaches
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
TWI636064B (zh) 2013-03-15 2018-09-21 安美基公司 人類ｐａｃ１抗體
CA2912678C (en) 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2015170281A1 (en) 2014-05-07 2015-11-12 Rainbow Medical Ltd Controlled tissue ablation techniques
WO2015195708A1 (en) * 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
JP6607509B2 (ja) * 2014-10-01 2019-11-20 オキシトーン バイオサイエンス ビー．ブイ． 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
RU2719416C2 (ru) * 2014-10-01 2020-04-17 Окситон Байосайенс Б.В. Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
CN111956803B (zh) 2014-10-20 2025-10-31 奥伊斯特普安生物制药公司 治疗眼部病状的方法
US9703929B2 (en) 2014-10-21 2017-07-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
BR112017010561A2 (pt) 2014-11-19 2017-12-26 Optinose As administração intranasal
CA3006962A1 (en) * 2014-12-01 2016-06-09 Achelios Therapeutics Inc. Methods and compositions for treating migraine and conditions associated with pain
HRP20231438T1 (hr) 2015-01-07 2024-06-07 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i načini uporabe
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
EP3872069A1 (de) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmazeutische zusammensetzungen mit perillylalkoholderivaten
JP6734258B2 (ja) * 2015-03-04 2020-08-05 栄研化学株式会社 オキシトシンの高感度測定法
JP6752223B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
CA2998708C (en) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
EP3390447A1 (de) 2015-12-15 2018-10-24 Amgen Inc. Pacap-antikörper und verwendungen davon
MX2018012351A (es) * 2016-04-12 2019-02-07 Trigemina Inc Formulaciones de oxitocina que contienen magnesio y metodos de uso.
WO2017181113A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
EP3457975A2 (de) 2016-05-18 2019-03-27 Pythagoras Medical Ltd. Spiralförmiger katheter
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
EP3687375A4 (de) * 2016-11-21 2022-01-19 Psomagen, Inc. Verfahren und system zur charakterisierung eines zustands im zusammenhang mit kopfschmerzen
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
WO2019060662A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
US10738110B2 (en) * 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
CN119868317A (zh) 2018-02-08 2025-04-25 南加州大学 穿透血脑屏障的方法
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
WO2020182322A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CN114072166A (zh) 2019-05-14 2022-02-18 泰加生物工艺学公司 用于治疗t细胞耗竭的组合物和方法
WO2021016190A1 (en) * 2019-07-19 2021-01-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for modulating drug-use disorders
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
BR112022003687A2 (pt) * 2019-08-29 2022-05-24 Univ New York Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina
US20240100120A1 (en) * 2019-10-11 2024-03-28 Board Of Regents, The University Of Taxas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
EP4093873A4 (de) 2020-01-24 2024-07-10 AIM ImmunoTech Inc. Verfahren, zusammensetzungen und impfstoffe zur behandlung einer virusinfektion
CA3189263A1 (en) * 2020-08-10 2022-02-10 Ziropa, Inc. Compositions and methods for topical delivery
US12384744B2 (en) 2021-09-29 2025-08-12 Ensysce Biosciences Inc. Enzyme-cleavable methadone prodrugs and methods of use thereof
JP2025504069A (ja) * 2022-01-27 2025-02-06 ベルナップ ファーマシューティカルズ， エルエルシー オキシトシンを使用した治療方法
WO2024102741A2 (en) * 2022-11-07 2024-05-16 AEON Biopharma, Inc. Compositions for use in treating headache disorders
WO2025064708A1 (en) * 2023-09-22 2025-03-27 The George Washington University Compositions comprising oxytocin and methods of treating opioid overdose
WO2025199179A2 (en) 2024-03-18 2025-09-25 Tonix Pharmaceuticals Holding Corp. Oxytocin peptide analogs

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413A (en) * 1849-05-01 Improved method of making wire-strengthened spoons
US464378A (en) * 1891-12-01 Toilet-paper holder
US2938891A (en) * 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) * 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US4213968A (en) * 1978-06-05 1980-07-22 Coy David Howard Enkephalin derivatives
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486441A (en) * 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US4885287A (en) * 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
ATE156704T1 (de) * 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9203769D0 (en) * 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
DE4312913A1 (de) * 1992-10-23 1994-10-13 Knauf Siegfried Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
WO1996020001A1 (en) * 1994-12-28 1996-07-04 Teikoku Hormone Mfg. Co., Ltd. Transmucosal preparation
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
KR100568436B1 (ko) * 1996-02-27 2007-04-25 데이진 가부시키가이샤 분말상경비투여조성물
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
JP2002531489A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系への神経栄養剤の投与
WO2000033814A2 (en) 1998-12-09 2000-06-15 Chiron Corporation Method for administering agents to the central nervous system
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
KR20020016831A (ko) * 1999-06-16 2002-03-06 나스텍 파마수티컬 컴퍼니 인코포레이티드 비내용 모르핀을 함유하는 의약 조성물 및 그 제조방법
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2001089359A (ja) * 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
AU1261501A (en) * 1999-12-06 2001-06-18 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
ATE300952T1 (de) * 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US6413499B1 (en) * 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
WO2001082914A2 (en) * 2000-04-28 2001-11-08 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
WO2002032449A2 (en) * 2000-10-13 2002-04-25 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US20070112052A9 (en) * 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
AU2002305066B8 (en) * 2001-03-23 2008-04-17 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US20030165434A1 (en) * 2001-04-20 2003-09-04 Chiron Corporation Delivery of polynucleotide agents to the central nervous system
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
WO2003089456A2 (en) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
WO2003093816A2 (en) 2002-05-02 2003-11-13 Bayer Healtchare Ag Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
WO2004019875A2 (en) 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Non-invasive methods to identify agents for treating pain
US7065445B2 (en) * 2002-11-27 2006-06-20 Mobilearia Vehicle passive alert system and method
WO2004062563A2 (en) 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
ES2315455T3 (es) * 2003-03-27 2009-04-01 Pantarhei Bioscience B.V. Uso de estrogenos para el tratamiento de infertilidad en maniferos machos.
KR101184833B1 (ko) 2003-04-08 2012-09-20 바이오템프트, 비.브이. Ｈｃｇ 절편들을 포함하는 점막 및 경구 투여용 조성물
US20040229025A1 (en) * 2003-04-11 2004-11-18 Chen Zhang Voltage tunable photodefinable dielectric and method of manufacture therefore
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
EP1742626A2 (de) 2004-04-23 2007-01-17 The Regents of The University of California Verbindungen und verfahren zur behandlung nichtentzündlicher schmerzen mit pparalpha-agonisten
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
AU2006217027A1 (en) * 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
EP1888043A4 (de) * 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions Octreotid-formulierungen mit kontrollierter freisetzung
US20060252685A1 (en) * 2005-05-04 2006-11-09 Gould Jeffrey D Treatment for sleep apnea
CA2620364A1 (en) * 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
CN101404174B (zh) * 2007-10-04 2010-06-09 威刚科技股份有限公司 电子信息储存装置

Also Published As

Publication number Publication date
JP5276982B2 (ja) 2013-08-28
US20090181880A1 (en) 2009-07-16
US20120028898A1 (en) 2012-02-02
US20100080797A1 (en) 2010-04-01
US20090317377A1 (en) 2009-12-24
EP2056800B1 (de) 2015-12-09
JP2009506076A (ja) 2009-02-12
JP2009506071A (ja) 2009-02-12
US8202838B2 (en) 2012-06-19
EP2179741A1 (de) 2010-04-28
EP1928484A2 (de) 2008-06-11
JP2013060464A (ja) 2013-04-04
AU2006282799A1 (en) 2007-03-01
WO2007025249A2 (en) 2007-03-01
WO2007025249A3 (en) 2007-04-19
WO2007025286A2 (en) 2007-03-01
CA2620364A1 (en) 2007-03-01
AU2006282799B2 (en) 2012-11-29
US8252745B2 (en) 2012-08-28
EP2056800A2 (de) 2009-05-13
IL189777A0 (en) 2008-08-07
JP2012207046A (ja) 2012-10-25
DE602006012513D1 (de) 2010-04-08
US20070054843A1 (en) 2007-03-08
US8258096B2 (en) 2012-09-04
US8501691B2 (en) 2013-08-06
US8198240B2 (en) 2012-06-12
JP5670415B2 (ja) 2015-02-18
US20090291900A1 (en) 2009-11-26
CA2620202C (en) 2016-10-04
EP2179741B1 (de) 2014-10-15
CA2620202A1 (en) 2007-03-01
US20070093420A1 (en) 2007-04-26
US20110250212A1 (en) 2011-10-13
EP1928484B1 (de) 2010-02-24
WO2007025286A3 (en) 2007-05-10
US20120322736A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
ATE458491T1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
DE602004023829D1 (de) Verfahren zur behandlung von sinuskopfschmerzen
EA202091708A1 (ru) Ингибиторы днк-пк
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
EA201100748A1 (ru) Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10
DE602004022424D1 (de) Proteasominhibitoren und verfahren zu deren anwendung
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
EP1507765A4 (de) Verfahren und zusammensetzungen zur behandlung von störungen des zentralen und peripheren nervensystems und hierfür geeignete neue verbindungen
EP2054058A4 (de) Pyruvatkinasehemmer und verfahren zur behandlung von erkrankungen
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602005020580D1 (de) Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
EA201890884A1 (ru) Способ и композиции для нежелательных и аномальных мышечных сокращений
ATE497492T1 (de) Reinigung von montelukast
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
EP4408412A4 (de) Zusammensetzungen und verfahren zur behandlung von kopfschmerzen
NZ759585A (en) Agent for preventing or treating brain atrophy
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
ATE408627T1 (de) Verfahren zur entfernung von fibronektin aus plasmafraktionen
EP3843731C0 (de) Ionenkanalinhibitorverbindungen zur behandlung von hypersensitivem husten
EP3927377A4 (de) Verfahren zur behandlung von infektionskrankheiten durch targeting des immun-checkpoints von nk-zellen
EA201590884A1 (ru) Способы лечения заболеваний печени

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties